DE102005020104

and DE102005020105. Guten Tag Schering AG,

Further along the road with the thiazolidinones, eh?  I like the title: New thiazolidinone without basic nitrogen, their production and use as drugs

Kinasepro is always happy to see more Plk1 inhibitors, but hey I’ll admit that I haven’t a clue whats going on with these – and now consider an earlier post on your analogous series, ummm, wrong. The only PDBs that give KP a hint as to what could be going on here are from some compounds bound to PI3K: 2A4Z, and 2A5U. O=C(N(CC)/C(S2)=C(C(NCC(F)(F)F)=O)\C#N)/C2=C/C1=C(C)N=CN1 O=C(N(CC)/C(S2)=C(C(NCC#C)=O)\C#N)/C2=C/C1=CC=C(N3CCCC3)C=C1

PLK1

So Kinasepro’s homework for the evening was to catch up on some of the PLK1 application literature just to see what’s out there. Expecting to see some Schering rip-offs, I was surprised to find a robust cast of characters playing there parts on the Polo-like stage.

Structurally it appears that there’s a cystein residue on the inside of the p-loop which most of these applications appear to attempt to exploit in one fasion or another.

Don’t care about PLK1? Then you may want to check back in a bit…

Did you know?

There’s apparantly a journal called: Expert Opinion on Therapeutic Patents.
And has been since 1990… Yah, me neither. I guess I can close my new blog then, Eh?

Inspired…

Inspired by better men, the likes of Tenderbutton, Milkshake, and Lowe, I’m actually going to try and get this bird off the ground.